Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has entered into a manufacturing agreement with G42 Medications Trading to produce the coronavirus (COVID-19) vaccines from China's Sinopharm.
The commercial production of the vaccine is forecast to start in April 2021, according to the company's disclosure to the Abu Dhabi Securities Exchange (ADX) on Monday.
The vaccine production's financial impact will appear from 2021 onwards.
It is noteworthy to mention that on Sunday, 28 March, Abu Dhabi-based leading technology company, G42, announced a new joint venture with Sinopharm CNBG to produce Hayat-Vax vaccine in the UAE, the first indigenous COVID-19 vaccine in the region.
